EU/3/04/220: Orphan designation for the treatment of glioma

Anti epidermal growth factor receptor antibody h-R3

Table of contents


On 2 September 2004, orphan designation (EU/3/04/220) was granted by the European Commission to Oncoscience AG, Germany, for anti epidermal growth factor receptor antibody h-R3 (cimazumab) for the treatment of glioma.

The sponsorship was transferred to Oncoscience GmbH, Germany, in September 2018.

Key facts

Active substance
Anti epidermal growth factor receptor antibody h-R3
Intended use
Treatment of glioma
Orphan designation status
EU designation number
Date of designation

Oncoscience GmbH
Osterbrooksweg 59
22869 Schenefeld
Tel. +49 40 300 97 990

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating